Where court’s LDT decision leaves labs
September 2025—The Food and Drug Administration’s efforts to regulate laboratory-developed tests as medical devices came to a decisive halt this spring with a ruling from the U.S. District Court …
Webinars and Sponsored Roundtables — Register Now
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
September 2025
How a core lab took back its outpatient business
September 2025—Angela Vetch, MPH, DLM(ASCP), is tired of reading about large commercial labs buying hospital laboratories’ outreach business. “There is an alternative to that story,” said Vetch, director of laboratory services at Kootenai Health, a three-hospital system in Coeur d’Alene, Idaho.
At AMP, latest on self-collection, avian influenza, and more
September 2025—Avian influenza, self-collection, and diagnostic stewardship in the microbiology laboratory are three topics of many that can be explored at the Association for Molecular Pathology meeting in Boston this November. Andrew Pekosz, PhD, heads a research laboratory at Johns Hopkins University that studies the replication and disease potential of emerging respiratory viruses.
Slide, tissue block repository ties past to AI’s future
September 2025—The largest repository of pathology slides and tissue blocks is becoming a powerful data repository with the promise to transform diagnosis and treatment through the use of artificial intelligence.
AMP case report: Germline variant not present in tumor?
September 2025—A 68-year-old male with a history of multiple myeloma was discovered to have a 3-cm carotid body mass on PET/CT. Surgery was consulted and determined that the lesion was not amenable to surgery. Radiology favored the lesion to be a paraganglioma, so plasma metanephrine and normetanephrine were tested and were negative. With paraganglioma as the working diagnosis, germline genetic testing was performed.
Layers of evaluation in thyroid carcinoma diagnosis
September 2025—In a CAP session last year on timely topics in thyroid tumors, Zubair W. Baloch, MD, PhD, shed light on poorly differentiated and differentiated high-grade follicular-derived carcinomas. “This is something new in the WHO 5th edition of the thyroid tumor classification scheme, and I think it’s about time that we have a different category and not really split them too much,” said Dr. Baloch, an editor and author of the 5th edition of the WHO Classification of Endocrine and Neuroendocrine Tumors. Why the category is new and what to know was part of the timely topics session, for which he paired up with Nikolina Dioufa, MD, PhD, MSc, who spoke about noninvasive follicular thyroid neoplasm with papillary-like nuclear features and follicular variant of papillary thyroid carcinoma.
Digital pathology leaders on momentum and AI
September 2025—Leaders of the Digital Pathology Association met online with CAP TODAY publisher Bob McGonnagle to talk about digital pathology and much that’s related: adoption, investment, and artificial intelligence tools. “Most people are playing catch-up,” Marilyn Bui, MD, PhD, past president of the DPA and a member of the association’s board of directors, said of digital pathology. Of AI and digital pathology, DPA Foundation president Michael Rivers of Roche Tissue Diagnostics said, “Over the next several years we’re going to see a transformation in pathology.”
Study to uncover new lab test ordering insight
September 2025—Enrollment is underway now for a new CAP study that will make it possible for individual and integrated laboratories to compare inpatient analyte volumes and identify ordering practice problems. “This study is the first by the CAP that will allow system laboratories to evaluate a quality metric—inpatient test utilization—across all laboratories within their system and in comparison to like system laboratories across the U.S. and beyond,” says Richard Brown, MD, former chair and now advisor to the CAP Quality Practices Committee, whose members developed the study.
From the President’s Desk
September 2025—It’s hard to believe that my two-year term as president of the CAP is already at its end. By the time you read this column, Jim Zhai, MD, will have been sworn in as our new president at the CAP annual meeting in Orlando. Serving as CAP president has given me amazing opportunities that I’m sure I would never have experienced otherwise. Perhaps the most rewarding has been the chance to meet hundreds of pathologists in the U.S. and across the globe and to witness firsthand the great work they’re doing for our profession, for the CAP, and particularly for our patients. The worldwide community of pathologists is truly impressive.
Clinical pathology selected abstracts
September 2025—Severe acute respiratory syndrome coronavirus 2 infection can lead to post-acute sequelae, or a condition known as long COVID. The World Health Organization defines long COVID as any symptoms that typically present within three months of acquiring COVID-19 and that persist for at least two months. Long COVID generally manifests as fatigue, pulmonary symptoms, and cognitive dysfunction. The biological mechanisms of long COVID are not well understood. Changes in the serotonin system may lead to cognitive changes, while mitochondrial changes may lead to fatigue, and complement and platelet activation to vascular disease.